EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Travere Therapeutics's enterprise value is $1,544.4 Mil.
Travere Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $273.5 Mil. Therefore, Travere Therapeutics's EV-to-Revenue for today is 5.65.
The historical rank and industry rank for Travere Therapeutics's EV-to-Revenue or its related term are showing as below:
TVTX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.52 Med: 4.71 Max: 16.89
Current: 5.65
During the past 13 years, the highest EV-to-Revenue of Travere Therapeutics was 16.89. The lowest was 1.52. And the median was 4.71.
TVTX's EV-to-Revenue is ranked better than 60.54% of 991
companies
in the Biotechnology industry
Industry Median: 8.34
vs TVTX: 5.65
Travere Therapeutics EV-to-Revenue Historical Data
The historical data trend for Travere Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Travere Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Travere Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Travere Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Travere Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Travere Therapeutics's EV-to-Revenue falls into.
Travere Therapeutics's current Enterprise Value is $1,544.4 Mil.
Travere Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $273.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics's share price for today is $16.11.
Travere Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.33.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Travere Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TVTX has been successfully added to your 